Bionano Genomics
BNGO
143 hedge funds and large institutions have $176M invested in Bionano Genomics in 2022 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 50 increasing their positions, 30 reducing their positions, and 19 closing their positions.
132% more call options, than puts
Call options by funds: $4.27M | Put options by funds: $1.84M
67% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 30
21% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 19
20% more capital invested
Capital invested by funds: $146M → $176M (+$29M)
2% more funds holding
Funds holding: 140 → 143 (+3)
0% more ownership
Funds ownership: 0.05% → 0.05% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.4M |
| 2 |
Millennium Management
New York
|
+$2.39M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.98M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.58M |
| 5 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$814K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$2.58M |
| 2 |
Mitsubishi UFJ Asset Management
Tokyo,
Japan
|
-$1.02M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$804K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$749K |
| 5 |
Two Sigma Investments
New York
|
-$694K |
BNGO Hedge Fund Activity: Q4 2022 in Review
143 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics (BNGO) for Q4 2022, worth a combined $176M — up 20% from $146M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new BNGO positions and 19 closed out — a net gain of 4 holders — while 50 added to existing stakes and 30 trimmed.
The largest buyer was BlackRock, adding an estimated $3.4M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $2.58M sold.
- 143 institutional investors held Bionano Genomics (BNGO) as of Q4 2022, up from 140 in Q3 2022.
- Funds reported $176M of Bionano Genomics stock for Q4 2022, up 20% quarter-over-quarter.
- 23 funds opened new Bionano Genomics positions in Q4 2022 and 19 closed out, a net change of +4 holders.
- The largest Bionano Genomics buyer in Q4 2022 was BlackRock, an estimated $3.4M added.
- The largest Bionano Genomics seller in Q4 2022 was Renaissance Technologies, an estimated $2.58M sold.
Based on aggregated 13F filings for Q4 2022.